Your English writing platform
Discover LudwigSuggestions(3)
Exact(5)
His treatment was to be six cycles of highly toxic chemotherapy followed by radiation.
Compared with patients who received standard therapy alone (a 5-HT3 antagonist plus dexamethasone), those who received aprepitant in addition to standard therapy had consistently better antiemetic protection that was well maintained over multiple cycles of highly emetogenic chemotherapy.
Aprepitant (Emend) is approved for use with other antiemetic drugs to prevent CINV in patients receiving initial and multiple cycles of highly and moderately emetogenic chemotherapy (Anon. 2006), based on the evidence from RCTs.
We conclude that the anti-emetic efficacy of a 5HT3 antagonist plus dexamethasone is not maintained over multiple cycles of highly emetogenic chemotherapy, and that the acute emesis protection is adversely influenced by protection failure in the delayed emesis phase.
In this multinational, phase III study, the safety and efficacy of NEPA, a convenient, fixed-dose antiemetic combination of netupitant, a highly selective NK1 receptor antagonist (RA), and palonosetron, a distinct 5-HT3 RA, were evaluated over multiple cycles of highly and moderately emetogenic chemotherapy.
Similar(55)
With the introduction of the 5HT3 antagonists in the 1990s and the combination with dexamethasone, complete acute emesis protection became possible in 70% of patients receiving a first cycle of highly emetogenic chemotherapy.
NEPA, an oral fixed-dose combination of netupitant, a highly selective NK1 receptor antagonist (RA), and palonosetron (PALO), a distinct 5-HT3 RA, was shown to be superior to PALO in preventing chemotherapy-induced nausea and vomiting after a single cycle of highly (HEC) or moderately (MEC) emetogenic chemotherapy in recent trials.
A cost-consequence study that included costs for aprepitant plus standard antiemetics for a hypothetical group of 1000 patients receiving a single cycle of highly emetogenic chemotherapy concluded that savings in overall direct medical costs would offset 58.7% (range 20 80%) of the incremental cost of adding aprepitant (Bell et al. 2004).
A cost-consequence study found that the costs of an aprepitant-containing regimen were $US536 154 compared with $US238 982 for standard antiemetic therapy in a hypothetical cohort of 1000 patients receiving a single cycle of highly emetogenic chemotherapy (Bell et al. 2004).
Parts 2 and 3 will be shown on May 11 and 18 at 9 p.m. 8 P.M. (13, 49) SUPERFISH In this "Nature" episode the filmmaker and biologist Rick Rosenthal takes to the seas to examine the life cycles of the highly prized billfish -- marlin, sailfish, spearfish and swordfish -- with stops at nurseries and secret undersea canyons along the Baja Peninsula of Mexico and the Great Barrier Reef off Australia.
Taken together, these results show that elevated DDX21 expression is required in order to maintain the viability and cell cycle progression of highly proliferative breast cancer cells.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com